Evidence map›Paper›PMID 42319577›Full record

ReviewMolecular biology reports2026

The bile acid-oxysterol axis in pulmonary arterial hypertension: from sterol trafficking to precision phenotyping and therapeutic opportunities.

Shuwei Weng, Chen Ding, Hailin Zhang, Yuxing Lai, Wei Zhuang, Dajun Chai

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shuwei WengCardiovascular Department, The First Affiliated Hospital, Key Laboratory of Metabolic Heart Disease in Fujian Province, Fujian Medical University, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province, Fuzhou, China.
Chen DingCardiovascular Department, The First Affiliated Hospital, Key Laboratory of Metabolic Heart Disease in Fujian Province, Fujian Medical University, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province, Fuzhou, China.
Hailin ZhangCardiovascular Department, The First Affiliated Hospital, Key Laboratory of Metabolic Heart Disease in Fujian Province, Fujian Medical University, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province, Fuzhou, China.
Yuxing LaiCardiovascular Department, The First Affiliated Hospital, Key Laboratory of Metabolic Heart Disease in Fujian Province, Fujian Medical University, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province, Fuzhou, China.
Wei ZhuangCardiovascular Department, The First Affiliated Hospital, Key Laboratory of Metabolic Heart Disease in Fujian Province, Fujian Medical University, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province, Fuzhou, China. zwfy006@163.com.
Dajun ChaiCardiovascular Department, The First Affiliated Hospital, Key Laboratory of Metabolic Heart Disease in Fujian Province, Fujian Medical University, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province, Fuzhou, China. dajunchai-fy@fjmu.edu.cn.

Funding

Fujian Provincial Health and Wellness Science and Technology Project 2025QNB012the Fujian Provincial Health and Family Planning Commission 2021ZQNZD005the Joint Funds for the Innovation of Science and Technology of Fujian Province 2021Y9123the Joint Funds for the Innovation of Science and Technology of Fujian Province 2023Y9107
6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) is increasingly recognized as a metabolically dysregulated and inflammatory vascular disease rather than a purely haemodynamic disorder. Among emerging metabolic pathways, the bile acid-oxysterol axis has gained attention as a potential link between sterol imbalance, endothelial dysfunction, and pulmonary vascular remodeling. This narrative review examines current evidence linking selected bile acid and oxysterol species to PAH phenotypes and discusses their potential mechanistic and translational implications. Human lung tissue studies, circulating metabolomics, and experimental models suggest that selected bile acid intermediates and oxysterol species may carry biological information beyond nonspecific disease severity, although their effects are molecule-specific, receptor-specific, and context-dependent rather than uniform across the entire metabolite class. In particular, recent work implicates disturbed lysosomal sterol trafficking and impaired endothelial lysosomal acidification, including NCOA7-related mechanisms, in generating pro-inflammatory sterol signatures that promote endothelial immunoactivation and worsen experimental PAH. At the same time, the biological origin and interpretation of these metabolites are likely heterogeneous, involving lung-intrinsic sterol remodeling, systemic gut-liver signals, and potential confounding from right-heart failure or congestive hepatopathy. We argue that the bile acid-oxysterol axis should not be viewed as uniformly causal or purely biomarker-like across all patients, but rather as a compartment- and endotype-dependent framework whose interpretation depends on the level of evidence considered. This framework has important implications for biomarker development, therapeutic targeting, and precision trial design, and identifies sterol trafficking and lysosomal homeostasis as promising areas for future investigation.

Indexed as

Bile Acids and SaltsOxysterolsPulmonary Arterial HypertensionSterolsAnimalsHumansPhenotypeBile Acids and SaltsOxysterolsSterolsBile acidsLysosomal dysfunctionOxysterolsPrecision phenotypingPulmonary arterial hypertension

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.